Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Maintains $89 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Hold rating on Biomarin Pharmaceutical (NASDAQ:BMRN) with a price target of $89.
July 25, 2024 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Hold rating on Biomarin Pharmaceutical with a price target of $89.
The Hold rating and maintained price target suggest that the analyst does not foresee significant short-term movement in the stock price. This neutral stance indicates stability but no immediate upside.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100